TNFRSF9 and melanoma: Therefore, α-CD137/α-PD-1 therapy outperformed the capacity α-CTLA-4/α-PD-1 or IL-2 treatment to synergize with SBRT in this mouse model, even though IL-2 in combination with SBRT-induced anti-tumor responses in human melanoma patients [27].